Immune Tolerance Network

Baseline Serum Metabolites as Predictors of Teplizumab Response in Individuals With Type 1 Diabetes

Abstract Aims/hypothesis Immunotherapies such as Teplizumab can preserve residual beta cell function in individuals with newly diagnosed type 1 diabetes (T1D), but treatment response is variable. Currently, no biomarker exists to identify individuals most likely to benefit from i...